OptimizeRx (OPRX) Set to Announce Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) will be posting its quarterly earnings results after the market closes on Wednesday, November 13th. Analysts expect OptimizeRx to post earnings of $0.06 per share for the quarter. OptimizeRx has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. OptimizeRx had a negative net margin of 21.53% and a negative return on equity of 5.97%. The company had revenue of $18.81 million for the quarter, compared to analysts’ expectations of $20.47 million. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptimizeRx Stock Down 1.9 %

OPRX stock opened at $5.11 on Wednesday. OptimizeRx has a one year low of $5.04 and a one year high of $16.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. The company has a fifty day moving average of $6.98 and a 200-day moving average of $9.20. The stock has a market capitalization of $93.63 million, a PE ratio of -5.11 and a beta of 1.32.

Analyst Upgrades and Downgrades

OPRX has been the subject of several research analyst reports. B. Riley initiated coverage on OptimizeRx in a research report on Thursday, July 25th. They issued a “buy” rating and a $18.50 price objective for the company. Barclays dropped their price target on OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating for the company in a research report on Monday, August 12th. Finally, Royal Bank of Canada lowered their price objective on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus target price of $14.50.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.